PTGX vs. MORF, AKRO, XNCR, DAWN, DVAX, KNSA, TARO, KURA, RCUS, and ANIP
Should you be buying Protagonist Therapeutics stock or one of its competitors? The main competitors of Protagonist Therapeutics include Morphic (MORF), Akero Therapeutics (AKRO), Xencor (XNCR), Day One Biopharmaceuticals (DAWN), Dynavax Technologies (DVAX), Kiniksa Pharmaceuticals (KNSA), Taro Pharmaceutical Industries (TARO), Kura Oncology (KURA), Arcus Biosciences (RCUS), and ANI Pharmaceuticals (ANIP). These companies are all part of the "pharmaceutical preparations" industry.
Morphic (NASDAQ:MORF) and Protagonist Therapeutics (NASDAQ:PTGX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, community ranking, media sentiment, analyst recommendations, risk, dividends and valuation.
Protagonist Therapeutics received 183 more outperform votes than Morphic when rated by MarketBeat users. Likewise, 59.73% of users gave Protagonist Therapeutics an outperform vote while only 59.54% of users gave Morphic an outperform vote.
Morphic presently has a consensus target price of $51.50, suggesting a potential upside of 70.36%. Protagonist Therapeutics has a consensus target price of $38.00, suggesting a potential upside of 20.75%. Given Protagonist Therapeutics' higher probable upside, equities analysts clearly believe Morphic is more favorable than Protagonist Therapeutics.
94.3% of Morphic shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 28.1% of Morphic shares are owned by insiders. Comparatively, 5.0% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Morphic has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.09, indicating that its stock price is 109% more volatile than the S&P 500.
Morphic's return on equity of 43.42% beat Protagonist Therapeutics' return on equity.
Protagonist Therapeutics has higher revenue and earnings than Morphic. Morphic is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Protagonist Therapeutics had 13 more articles in the media than Morphic. MarketBeat recorded 16 mentions for Protagonist Therapeutics and 3 mentions for Morphic. Morphic's average media sentiment score of 0.90 beat Protagonist Therapeutics' score of 0.55 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.
Summary
Protagonist Therapeutics beats Morphic on 13 of the 16 factors compared between the two stocks.
Get Protagonist Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PTGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Protagonist Therapeutics Competitors List
Related Companies and Tools
